Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer lesions ...

What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET [1] imaging agent, Illuccix® ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...